Literature DB >> 3987798

Increased peritoneal permeability in patients with peritonitis undergoing continuous ambulatory peritoneal dialysis.

M E McIntosh, W G Smith, B J Junor, G Forrest, M J Brodie.   

Abstract

The distribution of cefuroxime (250 mg) was studied in patients with renal failure undergoing continuous ambulatory peritoneal dialysis (CAPD). 10 uninfected patients received the drug intravenously and intraperitoneally, while 9 patients with peritonitis were randomly allocated to intravenous or intraperitoneal administration. Samples were taken over the first 6 hour dialysis period. In the infected patients, more drug (p less than 0.01) crossed into the peritoneal cavity following intravenous injection and reached the systemic circulation following intraperitoneal administration than in the uninfected group. This increased permeability of the peritoneal membrane during infection may result in unexpected systemic toxicity in patients treated with intraperitoneal antibiotics.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987798     DOI: 10.1007/bf00609690

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  7 in total

1.  Continuous ambulatory peritoneal dialysis. Three years' experience at the Mayo Clinic.

Authors:  S B Kurtz; V H Wong; C F Anderson; J P Vogel; J T McCarthy; J C Mitchell; R Kumar; W J Johnson
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

2.  Peritonitis in continuous ambulatory peritoneal dialysis. Laboratory and clinical studies.

Authors:  R Gokal; J M Ramos; D M Francis; R E Ferner; T H Goodship; G Proud; A J Bint; M K Ward; D N Kerr
Journal:  Lancet       Date:  1982-12-18       Impact factor: 79.321

3.  Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency.

Authors:  R A Walstad; O G Nilsen; K J Berg
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Pharmacokinetics of sulfamethoxazole--trimethoprim combination during chronic peritoneal dialysis: effect of peritonitis.

Authors:  E Singlas; J N Colin; J Rottembourg; J P Meessen; A de Martin; M Legrain; P Simon
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

5.  Peritoneal pharmacokinetics of gentamicin in man.

Authors:  M de Paepe; N Lameire; F Belpaire; M Bogaert
Journal:  Clin Nephrol       Date:  1983-03       Impact factor: 0.975

Review 6.  Cefuroxime: antimicrobial activity, Pharmacology, and clinical efficacy.

Authors:  B R Smith; J L LeFrock
Journal:  Ther Drug Monit       Date:  1983-06       Impact factor: 3.681

7.  Continuous ambulatory peritoneal dialysis.

Authors:  R P Popovich; J W Moncrief; K D Nolph; A J Ghods; Z J Twardowski; W K Pyle
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

  7 in total
  8 in total

Review 1.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Toxicologic and pharmacokinetic evaluation of a case of vancomycin intoxication during continuous ambulatory peritoneal dialysis.

Authors:  Y A Hekster; T B Vree; C M Weemaes; J J Rotteveel
Journal:  Pharm Weekbl Sci       Date:  1986-12-12

3.  Ertapenem pharmacokinetics and pharmacodynamics during continuous ambulatory peritoneal dialysis.

Authors:  Katie E Cardone; Darren W Grabe; Robert W Kulawy; Rachid Daoui; Joseph Roglieri; Shari Meola; George L Drusano; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

4.  Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.

Authors:  H Albin; J M Ragnaud; F Demotes-Mainard; G Vinçon; M Couzineau; C Wone
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Cefmenoxime kinetics during continuous ambulatory peritoneal dialysis.

Authors:  D A Sica; R E Polk; T M Kerkering; P Patterson; J Baggett
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 6.  Drug therapy in continuous ambulatory peritoneal dialysis patients.

Authors:  R Janknegt; J H Koelman
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

7.  Successful Treatment of a Pacemaker Infection with Intraperitoneal Daptomycin.

Authors:  Anne B Taegtmeyer; Nina Kononowa; Dominique Fasel; Manuel Haschke; Felix Burkhalter
Journal:  Perit Dial Int       Date:  2016 Jan-Feb       Impact factor: 1.756

8.  Preclinical assessment of adjunctive tPA and DNase for peritoneal dialysis associated peritonitis.

Authors:  Amanda L McGuire; Sophia C Bennett; Sally M Lansley; Natalia D Popowicz; Julius F Varano della Vergiliana; Daniel Wong; Y C Gary Lee; Aron Chakera
Journal:  PLoS One       Date:  2015-03-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.